BioCryst Pharmaceuticals Inc.

Stuart Grant joined the Senior Management Team at BioCryst in August of 2007. His recent experience with an established multi-national biotechnology company, coupled with his financial experience, add significantly to the depth of the BioCryst team. Prior to joining BioCryst, Mr. Grant was Chief Financial Officer at The Serono Group, based in Geneva, Switzerland. Operating as part of the leadership team, he was responsible for leading the Finance, Information Technology, and Communications functions, as well as driving the growth of profitability throughout the company. He was extensively involved in communicating strategy and tactics to the investor community. He has held a variety of Senior Operating and Financial positions in Europe and in the United States, and his drive and leadership skills will support the development of BioCryst in the next stages of the Company’s development.

William P. Sheridan joined BioCryst as Chief Medical Officer effective as of July 1, 2008. Dr. Sheridan s spent 15 years in drug development at Amgen Pharmaceuticals, Inc. before joining the Company, most recently as Vice President of North American Medical Affairs from March 2007 to November 2007. Dr. Sheridan organized and led Amgen s US Medical Affairs function, making significant contributions to the successful launch of many compounds, including Aranesp , Enbrel , Kineret , Neulasta and Sensipar . In addition to his most recent position at Amgen, Dr. Sheridan held titles at the Vice President level in International Medical Affairs, from March 2005 to February 2007; Global Health Economics, from January 2004 to January 2005; and Outcomes Research, US Medical Affairs, and Product Development from January 2002 to December 2003. Prior to joining Amgen, Dr. Sheridan practiced medicine at the Royal Melbourne Hospital in Victoria, Australia as Head of the Bone Marrow Transplant Service. He earned his MB BS degree (M.D. equivalent) at the University of Melbourne in Victoria. He is a board-certified fellow of the Royal Australasian College of Physicians, with a sub-specialty in hematology and medical oncology. After leaving Amgen in November 2007 and prior to joining the Company, Dr. Sheridan served as an independent consultant for pharmaceutical companies, including BioCryst.

Dr. Elliott Berger joined BioCryst in August 2007. Dr. Berger has more than 30 years of experience in the pharmaceutical industry, including over 25 years devoted to management of regulatory affairs supporting new drug and biologic development. Prior to joining BioCryst, he was Vice President, Regulatory Affairs and Quality Assurance, Head of Global Regulatory Strategy at EMD Pharmaceuticals, the North American subsidiary of Merck KGaA. As part of the EMD start-up team, Dr. Berger built and managed the EMD Regulatory Affairs, Clinical Quality Assurance and Drug Safety Groups, as well as the Global Regulatory Strategy Group. At EMD, Dr. Berger submitted and managed over 10 Investigational New Drug Applications in areas of oncology, diabetes, cardiovascular disease, and neurology. Dr. Berger also prepared and submitted the NDA for Cyanokit® which was approved within 6 months of submission to the FDA. Prior to EMD, Dr. Berger was a member of the Senior Executive Team at Astra Pharmaceuticals, most recently serving as Vice President, Regulatory Affairs. Dr. Berger received both his Ph.D. and M.S. degrees in Biometrics as well as his B.A. degree in Mathematics from Temple University.

David McCullough joined BioCryst in April, 2007. Prior to joining BioCryst Mr. McCullough served as Director, Global Corporate Development in the Ethical Pharmaceuticals Division at Merck KGaA in Darmstadt, Germany. In that position he was responsible for leading the company's efforts in evaluating the commercial value of specific product opportunities and in the case of the Serono SA acquisition, their entire company portfolio. Mr. McCullough led the commercial assessment of strategic and financial attractiveness of over 40 companies in oncology and other therapeutic areas. Prior to that position, Mr. McCullough was an integral part of the Business Operations and Market Research Team in the Oncology Business Unit of Eli Lilly and Company. Mr. McCullough received his Bachelor of Science degree from Western Illinois University.

Jonathan M. Nugent joined BioCryst in June 2005 as Vice President, Corporate Communications and Investor Relations. Prior to joining BioCryst, Mr. Nugent served as Senior Vice President and Director of Investor Relations at Burns McClellan, Inc., the country's largest independent healthcare public and investor relations firm. Working primarily in the agency's New York office, Mr. Nugent provided senior counsel to companies specializing in pharmaceutical discovery and development, drug delivery, medical devices and diagnostics, as well as to advisory and investment firms focusing on the biotechnology industry. He has extensive experience in providing strategic guidance in the areas of financial, scientific and regulatory communications, product launches, meetings before the FDA, IPO and follow-on financings, U.S. and European investors and crisis and issues management.

Mr. Robert Stoner joined BioCryst in January 2008. Mr. Stoner brings more than 25 years of progressive Human Resources experience to BioCryst, having worked in a diverse group of industries during his career. Prior to joining BioCryst, Mr. Stoner served as Senior Vice President Human Resources at Smith Breeden Associates, Inc. an institutional financial management company in Chapel Hill, North Carolina. Prior to joining Smith Breeden Associates, Mr. Stoner held the position of Vice President Human Resources at EMD Pharmaceuticals, the North American subsidiary of Merck KGaA. At EMD, Mr. Stoner was responsible for all human resource functions for multiple locations and was a member of the Global HR Team, coordinating and directing global HR initiatives within North America. Mr. Stoner participated in and graduated from the Merck University Executive Management Program, attending Northwestern University, Kellogg School of Management, Hong Kong University of Science and Technology and INSEAD in Paris. Mr. Stoner received his B.S. in Business Administration from Southern Illinois University.

Dr. Walter Gowan joined BioCryst in September 2006. Dr. Gowan has more than 20 years of experience in managing pharmaceutical product development programs. His experience includes many dosage forms including oral solutions, oral suspensions, tablets, capsules and sterile products (IV, IM and SC). Dr. Gowan has experience in all stages of product development including formulation development, process development, clinical supplies manufacturing, scale up, process validation, technology transfer, and the resolution of manufacturing issues. Many of his projects have resulted in US and European regulatory filings as well as several products. Prior to joining BioCryst, Dr. Gowan held the position of Senior Director Pharmaceutical Sciences at Cubist Pharmaceuticals where he was responsible for managing the internal and external pharmaceutical product development programs. Prior to joining Cubist, Dr. Gowan held the position of Director Product Development at Solvay Pharmaceuticals where he supervised two product development groups and managed the internal and external development of product candidates. Dr. Gowan received his Ph.D. in Pharmaceutics, B.S. in Pharmacy and B.S. in Biology from the University of Texas.

Dr. Babu directs a team of crystallographers and oversees the drug design and computer modeling efforts of the company. Having joined the Company in 1988, Dr. Babu was BioCryst's first full-time employee. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham.

Ms. Alane P. Barnes joined BioCryst in 2006. Prior to joining BioCryst, Ms. Barnes served as Senior Licensing Associate at the University of Alabama at Birmingham. From 1997, she was responsible for market and competitive analysis to determine intellectual property protection strategy, structuring and negotiation of strategic partnerships and collaborations, technology transfers, licenses and spin-out transactions including engagements for private financing. Ms. Barnes also served as a representative of UABRF and UAB at international biotech meetings and economic development meetings. From 1997 to 2003 Ms. Barnes practiced in a law firm and advised numerous companies on a broad range of issues including general corporate law, regulatory compliance, intellectual property, merger and acquisitions and shareholder agreements, health care law. Ms. Barnes graduated magna cum laude from Cumberland School of Law in 1997 and is a member of Curia Honoris. Ms. Barnes received both her B.S in Natural Science and a minor in Chemistry from the University of Alabama at Birmingham.

J. Michael Mills joined BioCryst in January 2005 as Controller. Effective January 2009, he was also named the Company s Principal Accounting Officer. As Controller and Principal Accounting Officer, he is responsible for the Company s external and internal financial reporting, accounting policy and systems, and internal controls. From September 2003 through January 2005, Mr. Mills served as a division controller with Compass Bank. He began his career in September 1997 with Ernst & Young LLP, providing accounting and auditing services to a variety of clients. Mr. Mills served as Manager with Ernst & Young LLP from October 2002 through August 2003. Mr. Mills is a Certified Public Accountant ( CPA ) and is a member of the American Institute of CPAs and the Alabama Society of CPAs.

Array

Randolph C. Steer, MD, Ph.D. became President of the Company on April 5, 2006. Dr. Steer has been an independent pharmaceutical, biotechnology and medical devices consultant since 1989, and has provided consulting services to OrthoLogic since 2002. He has a broad scientific, medical and business background, including extensive experience in pre-clinical, clinical and regulatory affairs, having held key management positions in leading corporations and having served as an advisor to many companies in the United States and abroad. Dr. Steer has also advised numerous venture capital firms, investment banks and independent investors on the commercial development of drugs, biologics, diagnostics and medical devices. He has served as Associate Director of Medical Affairs at Marion Laboratories; Medical Director at Ciba Consumer Pharmaceuticals (Ciba-Geigy Corporation); Vice President, Senior Vice President and Member of the Executive Committee at Physicians World Communications Group; Chairman, President and Chief Executive Officer of Advanced Therapeutics Communications International, a global drug regulatory group, and Chairman and Chief Executive Officer of Vicus.com, Inc. He is a member of the Board of Directors of Techne Corporation and BioCryst Pharmaceuticals. Dr. Steer received his MD degree from the Mayo Medical School and his Ph.D. from the University of Minnesota, where he also completed a residency and subspecialty fellowship in clinical and chemical pathology. He is a Fellow of the American College of Clinical Pharmacology.

William W. Featheringill was elected a Director in May 1995. Mr. Featheringill is President, Chief Executive Officer and director, since 1973, of Private Capital Corporation, a venture capital company. He currently serves as Chairman of Electronic Healthcare Systems, Inc., a system solutions provider to the ambulatory care industry, since June 1995, and Momentum Business Solutions, Inc., a telecom and VoIP company, since May 2001. Mr. Featheringill is a Director of Altec Industries, Inc., Southern Research Institute and the Birmingham Museum of Art, and serves as a Trustee of Vanderbilt University. Mr. Featheringill received a BE in Mechanical Engineering from Vanderbilt University, a J.D. degree from the Columbia University School of Law and a M.B.A. from the Columbia University Graduate School of Business.